Home > Oncology > Aspirin tied to higher risk of advanced cancer diagnosis and mortality

Aspirin tied to higher risk of advanced cancer diagnosis and mortality


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Journal of the National Cancer Institute
Reuters Health - 18/09/2020 - Older adults who take daily low-dose aspirin may be more likely than those who don't to be diagnosed with advanced cancers and to die from these malignancies, a randomized trial suggests. Researchers randomly assigned 19,114 community-dwelling adults 70 years and older in the U.S. and Australia 1:1 to take 100mg of aspirin or a placebo daily. Cancer history wasn't part of the exclusion criteria (19% of participants had a prior cancer diagnosis) but participants had to be healthy with a life expectancy of at least another five years and no diagnosis of cardiovascular disease, dementia, or physical disability. After a median follow-up of 4.7 years, there were 981 cancer events in the aspirin group and 952 in the placebo group and no statistically significant difference in all-cancer incidence between groups. But compared with the placebo group, participants in the aspirin group were more likely to be diagnosed with cancer that had ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on